Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology
Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)
DOI: 10.1002/cpdd.70079 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 01.07.2026. Verfasst von Amalia M Issa. Beteiligte Einrichtung: Editor-in-Chief, Clinical Pharmacology in Drug Development, American College of Clinical Pharmacology, Ashburn, VA, USA. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Editor-in-Chief, Clinical Pharmacology in Drug Development, American College of Clinical Pharmacology, Ashburn, VA, USA.
Zitieren
APA
Issa, A. M. (2026). Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70079
Vancouver
Issa AM. Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70079
BibTeX
@article{Issa2026,
author = {Issa, Amalia M},
title = {Beyond the “Undruggable”: What Pancreatic Cancer Teaches Us About the Next Evolution of Clinical Pharmacology},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cpdd.70079}
}
EUVIMED